Table 1 illustrates that the most significant obstacles to progress across these systems have not been a lack of physiological relevance, but unresolved pharmacologic, technological, or conceptual challenges
From payer friction to behavioral drop-off, GLP-1s are challenging pharma to rethink how success is measured in the obesity and diabetes markets
Lowering prices might encourage more people who might benefit from these medications to start using them. Recently, the IIFH brought together leading scientists, industry innovators and health care experts to examine how GLP-1-based therapies are transforming obesity and diabetes care
The text pretends to come from a doctor and states a weight-loss medication prescription has been approved
The development of novel drug delivery systems or formulations is also essential to improve patient compliance and reduce gastrointestinal adverse effects
Link American College of Rheumatology